Targeting alpha-synuclein or tau for treating neurodegenerative movement disorders

M. Lopez-Cuina, W.G. Meissner
Revue Neurologique. 2022-05-01; :
DOI: 10.1016/j.neurol.2022.03.010

Lire sur PubMed

Lopez-Cuina M(1), Meissner WG(2).

Author information:
(1)Department of Neurology, Hospital Universitario Reina Sofía, 14004 Cordoba,
Spain; University Bordeaux, CNRS, IMN, UMR 5293, 33000 Bordeaux, France.
(2)University Bordeaux, CNRS, IMN, UMR 5293, 33000 Bordeaux, France; CHU
Bordeaux, Service de Neurologie des Maladies Neurodégénératives, IMNc, 33000
Bordeaux, France; Department of Medicine, University of Otago, Christchurch, and
New Zealand Brain Research Institute, Christchurch, New Zealand. Electronic
address: .

The two commonest groups of neurodegenerative disorders causing movement
disorders are synucleinopathies and tauopathies. These disorders are
characterised by the accumulation of abnormally misfolded forms of α-synuclein
and tau proteins. Our current understanding of their pathogenesis suggests that
extracellular forms of these proteins are of major relevance to the mechanism of
pathology propagation throughout the brain and disease progression. The most
novel approaches to find disease-modifying therapies aim to reduce or block these
forms of tau and α-synuclein. This article reviews therapeutic strategies
targeting α-synuclein and tau protein which have entered clinical development.

Copyright © 2022 Elsevier Masson SAS. All rights reserved

Auteurs Bordeaux Neurocampus